MCID: PRM014
MIFTS: 29

Periampullary Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Periampullary Adenocarcinoma

MalaCards integrated aliases for Periampullary Adenocarcinoma:

Name: Periampullary Adenocarcinoma 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:8110
NCIt 46 C27322
UMLS 69 C1335377

Summaries for Periampullary Adenocarcinoma

MalaCards based summary : Periampullary Adenocarcinoma is related to adenocarcinoma and pancreatitis, and has symptoms including abdominal pain An important gene associated with Periampullary Adenocarcinoma is PIGR (Polymeric Immunoglobulin Receptor), and among its related pathways/superpathways are Pyrimidine metabolism (REACTOME) and Retinoblastoma (RB) in Cancer. The drugs Pancrelipase and Thrombin have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and endothelial.

Related Diseases for Periampullary Adenocarcinoma

Diseases related to Periampullary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 10.7
2 pancreatitis 10.4
3 neurofibromatosis, type iv, of riccardi 10.0
4 pancreatic cancer 9.8
5 somatostatinoma 9.8
6 paraganglioma 9.8
7 endotheliitis 9.8
8 hematologic cancer 9.6 CDKN1B DCK

Graphical network of the top 20 diseases related to Periampullary Adenocarcinoma:



Diseases related to Periampullary Adenocarcinoma

Symptoms & Phenotypes for Periampullary Adenocarcinoma

UMLS symptoms related to Periampullary Adenocarcinoma:


abdominal pain

Drugs & Therapeutics for Periampullary Adenocarcinoma

Drugs for Periampullary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 53608-75-6
2
Thrombin Approved, Investigational Phase 4
3 pancreatin Phase 4,Phase 2,Phase 1,Early Phase 1
4 Fibrin Tissue Adhesive Phase 4
5 Coagulants Phase 4
6 Hemostatics Phase 4
7
Ethanol Approved Phase 3 64-17-5 702
8 Central Nervous System Depressants Phase 3
9 Anti-Infective Agents Phase 3,Phase 2,Phase 1
10 Anti-Infective Agents, Local Phase 3
11
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
12
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
13
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
14
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
15
Fluorouracil Approved Phase 2 51-21-8 3385
16
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
17
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
19
Maleic acid Experimental Phase 2 110-16-7 444266
20
Cediranib Investigational Phase 2 288383-20-0 9933475
21
s 1 (combination) Phase 2
22
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
23 Immunosuppressive Agents Phase 2,Phase 1
24 Antimetabolites Phase 2,Phase 1
25 Antimetabolites, Antineoplastic Phase 2,Phase 1
26 Protein Kinase Inhibitors Phase 2,Phase 1
27 Liver Extracts Phase 2,Phase 1
28 Antiviral Agents Phase 2,Phase 1
29 Micronutrients Phase 2
30 Trace Elements Phase 2
31 Vitamin B Complex Phase 2
32 Vitamins Phase 2
33 Antidotes Phase 2
34 Protective Agents Phase 2
35 Calcium, Dietary Phase 2
36 Folate Nutraceutical Phase 2
37 Vitamin B9 Nutraceutical Phase 2
38
Capecitabine Approved, Investigational Phase 1 154361-50-9 60953
39
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
40
motexafin gadolinium Investigational Phase 1 156436-89-4 12047567
41 Histone Deacetylase Inhibitors Phase 1
42 Dermatologic Agents Phase 1
43 Photosensitizing Agents Phase 1
44
Menthol Approved Early Phase 1 2216-51-5 16666
45
Cefotaxime Approved 63527-52-6 5742673 456256
46
Cefoxitin Approved 35607-66-0 441199
47
Vitamin A Approved, Nutraceutical, Vet_approved Early Phase 1 68-26-8, 11103-57-4 445354
48 Orange Approved, Nutraceutical
49 Retinol palmitate Early Phase 1
50 Cephalosporins

Interventional clinical trials:

(show all 29)

# Name Status NCT ID Phase Drugs
1 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
2 The Effect of Application of TachoSil® in Pancreatoduodenectomy Recruiting NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
3 Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer Completed NCT00806611 Phase 3
4 Effect of Probiotics in Patients Undergoing Surgery for Periampullary Neoplasms Completed NCT01468779 Phase 3
5 SOX Sequential S-1 in Advanced Biliary Tract Carcinoma(BTC)and Pancreatic Cancer Unknown status NCT01811277 Phase 2 SOX sequential S-1
6 Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma Recruiting NCT01781728 Phase 2
7 Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers Terminated NCT01229111 Phase 2 cediranib maleate;oxaliplatin;leucovorin calcium;fluorouracil
8 Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers Terminated NCT00832637 Phase 2 Cisplatin;Erlotinib;Gemcitabine
9 Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer Withdrawn NCT00487851 Phase 2
10 Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer Completed NCT00983268 Phase 1 capecitabine;vorinostat
11 Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery Completed NCT00003798 Phase 1 motexafin gadolinium
12 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
13 Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy Unknown status NCT01913275
14 Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer Completed NCT02900950
15 Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers Completed NCT01134276
16 Fatigue and Pancreas and Bile Duct Cancer Study Completed NCT00902759 Early Phase 1
17 Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy Completed NCT00841607
18 Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Completed NCT02081131
19 Comparison Between Fully Covered Metal Stents and Plastic Stents in Preoperative Biliary Drainage Completed NCT01789502
20 Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer Completed NCT00409864
21 Preoperative Biliary Drainage With Metal Versus Plastic Stents in Periampullary Cancer Recruiting NCT02787512
22 Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region Recruiting NCT02780648 Early Phase 1
23 Impact of Additional DJ (Duodenojejunostomy)-Pexy on Reduction in Delayed Gastric Emptying Following Pylorus-preserving Pancreaticoduodenectomy: A Prospective, Randomized Controlled Trial Recruiting NCT02635399
24 Enteral Nutrition After Pancreaticoduodenectomy Recruiting NCT03150615
25 Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient Recruiting NCT02958059
26 High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Recruiting NCT02757859
27 EUS BD vs ERCP TP for Pancreatic Cancer Recruiting NCT03063554
28 Margin Status After Pancreaticoduodenectomy for Cancer Active, not recruiting NCT03267966
29 Comparing Three Dimension Laparoscopic Versus Open Pancreaticoduodenectomy Not yet recruiting NCT03138213

Search NIH Clinical Center for Periampullary Adenocarcinoma

Genetic Tests for Periampullary Adenocarcinoma

Anatomical Context for Periampullary Adenocarcinoma

MalaCards organs/tissues related to Periampullary Adenocarcinoma:

38
Pancreas, Liver, Endothelial

Publications for Periampullary Adenocarcinoma

Articles related to Periampullary Adenocarcinoma:

(show top 50) (show all 54)
# Title Authors Year
1
The clinical importance of tumour-infiltrating macrophages and dendritic cells in periampullary adenocarcinoma differs by morphological subtype. ( 28673320 )
2017
2
Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. ( 28518410 )
2017
3
The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma. ( 27488532 )
2016
4
Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. ( 27070783 )
2016
5
Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma. ( 26590090 )
2016
6
The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. ( 27275582 )
2016
7
Management of periampullary adenocarcinoma by pancreaticoduodenectomy at a regional teaching hospital. ( 26261725 )
2015
8
Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. ( 26362587 )
2015
9
Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma. ( 26028992 )
2015
10
Serum N-Glycome Characterization in Patients with Resectable Periampullary Adenocarcinoma. ( 26515733 )
2015
11
Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. ( 26361410 )
2015
12
A prospective, randomized, double-blind, placebo controlled trial on the efficacy of ethanol celiac plexus neurolysis in patients with operable pancreatic and periampullary adenocarcinoma. ( 25667135 )
2015
13
Use of a standardized diagnostic approach improves the prognostic information of histopathologic factors in pancreatic and periampullary adenocarcinoma. ( 24731283 )
2014
14
Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. ( 25323550 )
2014
15
A case of periampullary adenocarcinoma in neurofibromatosis type 1. ( 25436139 )
2014
16
Reduced expression of the polymeric immunoglobulin receptor in pancreatic and periampullary adenocarcinoma signifies tumour progression and poor prognosis. ( 25397670 )
2014
17
Mixed periampullary adenocarcinoma and somatostatinoma with small bowel gastrointestinal stromal tumour in neurofibromatosis type 1. ( 25435578 )
2014
18
FAP related periampullary adenocarcinoma. ( 23792481 )
2013
19
Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma. ( 23601033 )
2013
20
Ampullary and periampullary adenocarcinoma: new challenges in management of recurrence. ( 23474562 )
2013
21
Large retroperitoneal paraganglioma concurrent with periampullary adenocarcinoma. ( 24523807 )
2013
22
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. ( 22782416 )
2012
23
Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma. ( 22551547 )
2012
24
Adjuvant chemotherapy for resected periampullary adenocarcinoma. ( 23149995 )
2012
25
Results of pancreaticoduodenectomy in patients with periampullary adenocarcinoma: perineural growth more important prognostic factor than tumor localization. ( 18580212 )
2008
26
Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. ( 18547417 )
2008
27
Pancreaticoduodenectomy with extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. ( 17336242 )
2007
28
Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. ( 17084719 )
2006
29
Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinoma. ( 15978737 )
2005
30
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival. ( 16332474 )
2005
31
Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. ( 15531230 )
2004
32
Neoadjuvant therapy and biliary decompression lower biliary and pancreatic juice vascular endothelial growth factor levels in patients with periampullary adenocarcinoma. ( 15011922 )
2004
33
Cyclin D1 and bax influence the prognosis after pancreatoduodenectomy for periampullary adenocarcinoma. ( 15532837 )
2004
34
Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. ( 12559179 )
2003
35
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. ( 12192322 )
2002
36
Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. ( 11677994 )
2001
37
Survival after pancreaticoduodenectomy for periampullary adenocarcinoma: an update. ( 11520088 )
2001
38
The Johns Hopkins experience with pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. ( 10939866 )
2000
39
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. ( 11072167 )
2000
40
Prospective study of gastric outlet obstruction in unresectable periampullary adenocarcinoma. ( 10594205 )
2000
41
Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. ( 10421536 )
1999
42
Periampullary adenocarcinoma: analysis of 5-year survivors. ( 10561100 )
1999
43
Implications of histological grade of tumour for the prognosis of radically resected periampullary adenocarcinoma. ( 10533763 )
1999
44
Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. ( 10359359 )
1999
45
Primary nonampullary/periampullary adenocarcinoma of the duodenum. ( 9843337 )
1998
46
Periampullary adenocarcinoma: analysis of 5-year survivors. ( 9637545 )
1998
47
A study of forty-nine consecutive Whipple resections for periampullary adenocarcinoma. ( 9240943 )
1997
48
Improved results for resection of periampullary adenocarcinoma. ( 9184871 )
1996
49
Clinical behavior and prognostic factors of periampullary adenocarcinoma. ( 7487210 )
1995
50
Mixed cellular population in primary and metastatic periampullary adenocarcinoma of the duodenum: report of a case. ( 7633200 )
1994

Variations for Periampullary Adenocarcinoma

Expression for Periampullary Adenocarcinoma

Search GEO for disease gene expression data for Periampullary Adenocarcinoma.

Pathways for Periampullary Adenocarcinoma

GO Terms for Periampullary Adenocarcinoma

Biological processes related to Periampullary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleobase-containing compound metabolic process GO:0006139 8.62 DCK SLC29A1

Sources for Periampullary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....